Abstract: A process for preparing a fluorine-containing copolymer by an emulsion polymerization method in the presence of aqueous ammonia as a pH modifier, and a molded article obtainable by melt molding or crosslinking molding the fluorine-containing copolymer. In preparing the fluorine-containing copolymer by coagulation of the fluorine-containing copolymer contained in a fluorine-containing copolymer dispersed aqueous solution, it is preferred to use a cationic surfactant and a water soluble organic solvent as a coagulating agent used for the above coagulation. The surfactant is preferably represented by the, formula (R4N+)X? wherein R is an alkyl group of 1 to 22 carbon atoms, a fluoroalkyl group obtainable by fluorine substituting at least a part of hydrogen atoms present in the above alkyl group or hydrogen, four R's may be the same or different provided that they are not hydrogen atoms simultaneously, and X is a halogen atom.

Abstract: The present invention provides: a water-absorbing agent which has excellent urine resistance; a water-absorbing agent which has not only excellent urine resistance, but also excellent absorption properties that are stable to any composition of urine and show little change with time; and production processes and uses for these water-absorbing agents. The present invention water-absorbing agent exhibits a specific or larger value of absorption capacity under a load in a process in which the absorption capacity under a load is measured in a new manner using a specific liquid to be absorbed, and the present invention provides an absorbent matter and an absorbent article which display a specific or larger value of new absorption index as is, for example, led from the absorption capacity under a load or from the resin concentration using the above water-absorbing agent. The present invention further provides a production process for a water-absorbing agent having the above specific parameter.

Abstract: The present invention is directed to a method for preparation of polyolefins containing exo-olefin chain ends. The method involves quenching a cationic quasi-living polyolefin polymer system with one or more hindered secondary or tertiary amines.

Abstract: A producing method of resin particles, which comprises at least an emulsification step of emulsifying a composition containing at least a polymerizable monomer and a polymerization step to form droplets of the composition, and a polymerization step of polymerizing the polymerizable monomer in the droplets to synthesize resin particles, wherein the composition is one selected from Composition A, Composition B, or Composition C: (Composition A): a composition containing a vinyl-based monomer, lactone, a vinyl-based monomer polymerization catalyst for polymerizing the vinyl-based monomer, and a lactone polymerization catalyst for polymerizing the lactone (Composition B): a composition containing a polyester resin, lactone, and a lactone catalyst for polymerizing the lactone (Composition C): a composition containing a vinyl-based monomer, a cyclic keteneacetal compound represented by the following general formula (1), and a radical polymerization initiator (in the general formula (1), R represents a ch

Abstract: A catalyst composition for the polymerization of propylene comprising one or more Ziegler-Natta procatalyst compositions comprising one or more transition metal compounds and one or more monoesters of aromatic carboxylic acid internal electron donors; one or more aluminum containing cocatalysts; and a mixture of two or more different selectivity control agents, said SCA mixture comprising from 98.0 to 99.9 mol percent of one or more esters of one or more aromatic monocarboxylic acids or substituted derivatives thereof, and from 2.0 to 0.1 mol percent of one or more alkoxysilane compounds.

Abstract: External donor systems, catalyst systems and olefin polymerization processes are described herein. The external donor systems generally include a first external donor represented by the general formula SiR2m(OR3)4-m, wherein each R2 is independently selected from alkyls, cycloalkyls, aryls and vinyls, each R3 is independently selected from alkyls and m is from 0 to 4. The external donor systems further include a second external donor represented by the general formula SiR4m(OR5)4-m, wherein each R4 is independently selected from alkyls, cycloalkyls, aryls and vinyls, each R5 is independently selected from alkyls, m is from 0 to 4 and at least one R4 is a C3 or greater alkyl.

Abstract: The present invention relates to a process for producing a buten-1-based polymer satisfying the following requirements (a), (b) and (c): (a) a crystalline resin having a melting point (Tm-D) of 0 to 100° C., the melting point being defined as a top of a peak observed on a highest-temperature side in a melting endothermic curve obtained by a differential scanning calorimeter (DSC) when a sample is held in a nitrogen atmosphere at ?10° C. for 5 min and then heated at a temperature rise rate of 10° C./min; (b) a stereoregularity index represented by (mmmm)/(mmrr+rmmr) of 20 or less; and (c) a weight-average molecular weight (Mw) of 10,000 to 1,000,000 and a ratio (Mw/Mn) of weight-average molecular weight to number-average molecular weight of 4.0 or less; a modified buten-1-based polymer produced by modifying the buten-1-based polymer with a radical polymerization initiator and an organic acid; and an adhesive composition containing the modified buten-1-based polymer.

Abstract: Partially biodegradable hydrogel that changes its volume and shape in response to change in pH and/or temperature is prepared by UV irradiation of composition comprising dextran-maleic acid monoester and N-isopropylacrylamide.

Abstract: Acyclic diene metathesis (ADMET) has been utilized in the synthesis of carbosilane and carbosiloxane polymers bearing a latent reactive methoxy-functional group on each repeat unit. The polymerization results in a linear thermoplastic polymer. The latent reactive methoxy groups remain inert during polymerization; however, exposure to moisture triggers hydrolysis and the formation of a chemically cross-linked thermoset. The thermoset's properties can be modified by varying the ratio of carbosilane and carbosiloxane repeat units in the final material. Also, increasing cross-link density by using cross-linkable chain-end groups and increasing the run length of the soft phase, maximizing phase separation and elasticity, allows for the synthesis of elastic thermosets exhibiting good tensile strength. Adding a trifunctional ADMET active chain-end cross-linker to the system improved the mechanical behavior of the resulting polymer.

Abstract: The invention is directed to polyester processes that utilizes a pipe reactor in the esterification, polycondensation, or both esterification and polycondensation processes. Pipe reactor processes of the present invention have a multitude of advantages over prior art processes including improved heat transfer, volume control, agitation and disengagement functions.

Abstract: A method for producing a borohydride is described and which includes the steps of providing a source of borate; providing a material which chemically reduces the source of the borate to produce a borohydride; and reacting the source of borate and the material by supplying heat at a temperature which substantially effects the production of the borohydride.

Abstract: The present invention provides methods for identifying a class of peptides referred to as replikins and methods of using replikins to stimulate the immune system of a subject. The method of identifying replikin peptides is based on identifying amino acid sequences comprising 7 to about 50 amino acids that contain (1) at least one lysine residue located six to ten residues from a second lysine residue; (2) at least one histidine residue; and (3) at least 6% lysine residues.

Abstract: The present invention is to provide a tissue-specific transporter inhibitor which is not absorbed through the digestive tract and can prevent deterioration in the QOL of a patient caused by diet therapy, and a therapeutic drug for tissue dysfunction diseases and a therapeutic drug for suppressing the progress of chronic renal failure containing the inhibitor as an active ingredient. A tissue-specific transporter inhibitor which is not absorbed through the digestive tract is constructed by introducing a dipeptide which is a ligand of an oligopeptide transporter 1 into a supramolecular structure polyrotaxane wherein its structurally modified active residue is expected to be excellent in the interaction with a transmembrane transporter.

Abstract: The present invention concerns compositions and methods for the treatment of cancer. More specifically, the present invention relates to identification of aminopeptidase A (APA) as a functional target in neo-vasculature, e.g., tumor vasculature; the present invention also relates to targeting peptides and antibodies specific for APA which may be used for cancer therapies.

Abstract: An amino acid sequence Arg-Lys-Met-Leu-Lys-Ser-Thr-Arg-Arg-Gln-Arg-Arg (SEQ ID NO:1) functions as a protein transduction domain (PTD) and is capable of delivering small molecules, proteins, and nucleic acids to an intracellular compartment of a cell. An amino terminal lysine linker improves the efficiency of the PTD. A nuclear localization signal can be used to target the PTD to a cell's nucleus. The PTD can be used in PTD-cargo moiety complexes that can reversibly immortalize cells and increase cell viability in culture.

Abstract: Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.

Abstract: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.

Abstract: This invention relates to a process for purifying a polypeptide, a capture tag useful for purifying a polypeptide and a periodate-cleavable amino acid derivative useful for purifying a polypeptide. The polypeptide to be purified comprises a vicinal-amino-thiol, vicinal-amino-hydoxyl, vicinal-diol or vicinal-diamino group. The purification process comprises attaching the polypeptide to a purification matrix by contacting the polypeptide with a purification matrix comprising aldehyde or ketone groups under conditions which favor formation of a heterocyclic ring system, washing the purification matrix, and releasing the polypeptide from the purification matrix.

Abstract: Anti-angiogenic polypeptides A61 or p22 are disclosed. Also disclosed are methods of making the polypeptides and methods of treating subjects having angiogenic diseases or conditions.

Abstract: Hybrid antigens comprising an antigenic domain and improved heat shock protein binding domains are described which are useful for the induction of an immune response to the antigenic domain and thus can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.

Abstract: FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed.

Abstract: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases.

Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Abstract: Complexes of a protein selected from the group consisting of VEGF-B167, VEGF-C, VEGF-D and processed VEGF-B186 and analogs thereof and the neuropilin-1 (NP-1) receptor, the extracellular domain or a ligand-binding fragment or analogue thereof; the use of such complexes in assays for growth factor proteins having substantially the same binding affinity for a cell surface receptor as VEGF-B167, VEGF-C, VEGF-D or processed VEGF-B186 and/or in promoting or antagonizing a cellular response mediated by VEGF-B167, VEGF-C, VEGF-D and/or processed VEGF-B186; and specific binding partners, e.g. antibodies, for such complexes.

Abstract: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.

Abstract: The present invention relates to the identification of novel nucleic acid molecules and the proteins encoded by these nucleic acid molecules, as well as their production for use as therapeutics, diagnostics and for research purposes.

Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also, provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.

Abstract: An isolated and purified human skeletal muscle-specific ubiquitin-conjugating enzyme comprising the amino acid sequence shown in SEQ ID NO: 22 is disclosed. The use of the genes make it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases.

Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

Abstract: The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-?.

Abstract: Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.

Abstract: An intermediate for vinblastine synthesis represented by general formula A. general formula A. (in the formula, R1, R2, R3 and R4 are the group selected independently from the group consisting of H, lower alkyl group, lower alkoxy group, halogen, lower perfluoroalkyl group, lower alkylthio group, hydroxy group, amino group, mono- or di-alkyl or acylamino group, lower alkyl or arylsulfonyloxy group. R5 is H, or a lower alkyl group or a substituted or non-substituted aryl group, R6 is an alkyl group of carbon number 4 or less, R7 is a substituted or non-substituted aryl group, R8 is a substituted or non-substituted aryl group or lower alkyl group and R9 is an acyl group or trialkylsilyl group.

Abstract: The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.

Abstract: The present invention relates to novel enzymatic substrates with the following general formula: where R1, R2, R3, R4, R5, R6, A and X are as defined in claim 1, the reaction media comprising the same and the use thereof for the detection and/or identification and/or quantification of microorganisms expressing at least one peptidase activity.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Substituted bicyclic imidazo-3-yl-amine compounds are provided, as well as processes for the production thereof and pharmaceutical formulations containing these compounds. The use of these compounds for the production of pharmaceutical formulations and related methods of treatment are also provided.

Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

Abstract: Provided are a compound for a molecular electronic device which includes a terpyridine-ruthenium organic metal compound including a thiol anchoring group of the formula below, a method of synthesizing the compound and a molecular electronic device including a molecular active layer obtained from the compound. In the formula, R1 and R2 are each a thioacetyl group or a hydrogen atom, at least one of R1 and R2 is a thioacetyl group, and m and n are each integers from 0 to 20. The molecular active layer, which is formed by self-assembling the compound on an electrode surface, composes a switching element and a memory element.

Abstract: Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.

Abstract: The present invention relates to benzopyran derivatives substituted with a thioxobenzoxazole derivative, or pharmaceutically acceptable salts thereof, processes for preparing the same and a pharmaceutical composition containing the above as an effective ingredient Benzopyran derivatives substituted with thioxobenzoxazole derivatives, represented in <Formula 1>, have the function of protecting heart from ischemia-reperfusion both in vivo and in vitro, so that a pharmaceutical composition containing benzopyran derivatives substituted with thioxobenzoxoazole derivatives or pharmaceutically acceptable salts thereof of the present invention as an effective ingredient can be effectively used for the protection of tissues influenced by ischemia-reperfusion, for example, for the protection of heart, nervous cells, brain, retinal cells, storage organs, etc, and for the treatment of diseases caused by ischemia-reperfusion.

Abstract: Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.

Abstract: The present invention relates to hetaryl-substituted pyrazolidine derivatives of the formula (I) in which Het, A, D and G are as defined above, to a plurality of processes for their preparation and to their use as pesticides and/or herbicides. Moreover, the invention relates to selective herbicidal compositions comprising both the hetaryl-substituted pyrazolidinedione derivatives and a crop plant compatibility-improving compound.

Abstract: A process is provided for preparing a dipeptidyl peptidase IV inhibitor of the structure is treated with TFAA in isopropyl acetate to protect the tertiary hydroxyl group as a trifluoroacetate group to form 4 (which is a novel intermediate) which is converted to acid chloride compound 5 (which is a novel compound) using Vilsmeier reagent or other chloro reaget and coupled with compound 6 in a heterogeneous mixture of ethyl acetate and aqueous bicabonate to give compound 7 The N,O-bis(trifluoroacetyl) groups of compound 7 are deprotected to give free base compound 10.

Abstract: Lactones are prepared by catalytic carbonylation of oxiranes using a catalyst system comprising a) at least one cobalt compound as component A and b) at least one metal compound of the formula (I) as component B, MXxRn-x ??(I) where M is an alkaline earth metal or a metal of group 3, 4 or preferably 12 or 13 of the Periodic Table of the Elements, R is hydrogen or a hydrocarbon radical which may be substituted on the carbon atoms other than the carbon atom bound to M, X is an anion, n is a number corresponding to the valence of M and x is in the range from 0 to n, with n and x being selected so that the compound is uncharged, as catalyst.

Abstract: Provided are novel hetero-polycyclic compounds having a specific structure, color-changing material compositions comprising (A) a fluorescent coloring matter comprising at least one of the hetero-polycyclic compounds described above and (B) a binder material, color-changing films comprising the above hetero-polycyclic compounds, coloring matters comprising the above hetero-polycyclic compounds, and pigments or dyes comprising the hetero-polycyclic compounds described above, and provided are color-changing material compositions which are not deteriorated in a color-changing performance even after used for long time and which are prevented from being unusable due to deposition of coloring matters during storage and color-changing films produced by using the same, and novel hetero-polycyclic compounds, coloring matters and pigments or dyes which actualize them.

Abstract: The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.